NDAINTRAOCULARSOLUTIONPriority Review
Approved
Sep 1972
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MIOSTAT (carbachol) is a small-molecule cholinergic agonist administered as an intraocular solution during ophthalmic surgery. It causes pupillary constriction (miosis) and is used to achieve and maintain miosis intraoperatively. The drug works by directly stimulating cholinergic receptors in the eye.
LOE Approaching
As LOE approaches, the brand team is likely contracting; expect focus on cost management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients
Started Mar 2025
119 enrolled
Presbyopia
Career Relevance
Working on MIOSTAT offers limited career growth due to its mature lifecycle stage and approaching loss of exclusivity. Roles focus on operational efficiency, pricing defense, and managed decline rather than innovation or market expansion.
Brand Manager
Worked on MIOSTAT at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.